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Mouse modelRhinoviruses (RVs) are picornaviruses that are causative agents of the majority of upper respiratory tract infec-
tions, or “common colds,” in humans. RVs infect both the upper and lower respiratory tract, and in addition to
the common cold may also cause pneumonia, complications in patients with chronic lung diseases such as cystic
ﬁbrosis, and asthma exacerbations. Convenient animal models are not available to study the pathogenesis of rhi-
novirus-induced illness. Rhinovirus RV1A replicates poorly in mouse cells; variants with improved replication
were selected by serial passage throughmouse embryonic ﬁbroblasts andmouse lung epithelial cells. Adaptation
for improved growth inmouse cells was mediated by amino acid changes in the RV1a non-structural protein 3A.
Mouse cell-adapted RV1Awas capable of productively infectingmice inwhich the airwaywas subjected to chem-
ical permeabilization. Amousemodel for RV infectionwill permit studies of RVpathogenesis andmay identify tar-
gets for therapeutic intervention.asmussen),
ersity of Washington, Seattle,
rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Rhinovirus infections cause themajority of common colds, aswell as
serious acute exacerbations of asthma, chronic lung diseases such as
chronic obstructive pulmonary disease (COPD) (Varkey and Varkey,
2008), and pneumonia in infant, elderly, and immunosuppressed pa-
tients. Common colds aremajor economic burdens, resulting inmassive
healthcare costs and decreased working productivity. Asthma, COPD,
and pneumonia are all serious conditions that can lead to severe mor-
bidity resulting in hospitalization, and which are often fatal. Because
of the diversity of rhinovirus serotypes, there are no vaccines to prevent
rhinovirus infection, and no effective treatment.
The development of novel therapies that could reduce the incidence
or severity of rhinovirus infections is hindered by the lack of a practical
animal model. Studies performed in human volunteers and non-
human primates are limited in scope and often prohibitively expensive
(Xatzipsalti and Papadopoulos, 2007). Small-animal models developed
for rhinovirus infection are also limited, as there is no current model
that supports robust replication of infectious virus comparable to a clin-
ically relevant human infection. These models require that mice are ei-
ther immunosuppressed (Yin and Lomax, 1986) or are accompanied by
modest production of infectious virus in the respiratory tract (Bartlett
et al., 2008).
Amajor obstacle to development of a small animalmodel thatmean-
ingfully reproduces many of the clinical features of human rhinovirusinfection is that mouse cells are not permissive for replication of most
rhinovirus types. The block to replication appears to be at the level of
RNA replication (Yin and Lomax, 1983). Furthermore, the ~90 rhinovi-
rus types that bind human intercellular adhesion molecule 1 (ICAM-1)
cannot enter mouse cells because murine ICAM-1 does not bind the
viral capsid (Bella and Rossmann, 1999, 2000).
Several rhinovirus types have been selected for growth in mouse
cells (Harris and Racaniello, 2003, 2005; Yin and Lomax, 1983, 1986).
Repeated passages of RV2, RV16, and RV39 between human cells and
mouse ﬁbroblasts lead to the isolation of host range variants capable
of robust replication in mouse cells. The genomes of these viruses
havemutations leading to amino acid changes in the 2BC and 3A region
of the viral genome. By passing RV1a in mouse lung epithelial cells, we
isolated viruseswith amino acid changes in the 3Aprotein that canmul-
tiply in mouse cells and in the respiratory epithelium of mice.Results
Isolation of mouse cell-adapted RV1A variants
RV1A was subjected to alternate passages in cultured in MDA5−/−
murine embryonic ﬁbroblasts and HeLa cells, or by serial passage
throughMEFs with ampliﬁcation in HeLa cells as needed. MEFs deﬁcient
in MDA5, the cytoplasmic sensor of picornavirus infection (Kato et al.,
2006; Wang et al., 2010) were used for viral passage to diminish the in-
terferon response and possibly enhance HRV replication. MDA5 binds
double-stranded viral RNA and induces innate antiviral immune re-
sponses, andhas also been shown tomediate airway epithelial responses
in response to RV infection (Wang et al., 2009). Following 35 cell pas-
sages in these cells, virus was passaged 27 times in LA4 mouse lung
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ing isolates designated RV1A/M2M and RV1A/M2H, respectively.
Mouse-adaptation of selected viruses was assessed by one-step
growth analysis. In HeLa cells, RV1A/M2M and RV1A/M2H replicated
at a slightly reduced rate compared to wild-type RV1A at both MOI=1
(Fig. 1a) andMOI=0.1 (Fig. 1c). In LA4 cells, RV1A/M2MandRV1A/M2H
replicated at a faster rate and to higher titers thanwild-type RV1A at both
MOI=1 (Fig. 1b) and MOI=0.1 (Fig. 1d), indicating that both variants
are adapted for more efﬁcient growth in mouse airway epithelial cells.
Cytopathic effect over the course of virus replication was determined
in HeLa and LA4 cells bymeasuring cell viability by trypan blue exclusion.
Cells infected with all viruses displayed cytopathic effect compared to
mock-infected HeLa cells (Fig. 2a). The viability of HeLa cells infected
with wild-type RV1A steadily decreased; a slightly slower decrease in
cell viability was observed in cells infected with RV1A/M2M and
RV1A/M2H. Very little cytopathic effectwas observed in LA4 cells infected
with wild-type RV1A compared to RV1A/M2M and RV1A/M2H, both of
which produced steady decreases in cell viability (Fig. 2b). The increased
replication of mouse-adapted RV1A produces higher levels of cell killing
in mouse cells compared to wild-type virus, perhaps because the viruses
replicate to higher levels.
Genetic basis of adaptation
To identify the changes that accompany enhanced replication in
mouse cells, complete nucleotide sequences of the genomes of wild-Fig. 1. Growth of mouse-adapted RV1A in LA4 cells. Yields of infected cells were determine
cells (solid lines, ﬁlled symbols), LA4 cells (dashed lines, empty symbols), wild-type RV1A (s
at MOI=1 in HeLa and LA4 cells. B. Replication of RV1A/M2H at MOI=1 in HeLa and LA4 cetype RV1A, RV1A/M2M, andRV1A/M2Hwere determined. The genomes
of both RV1A/M2M and RV1A/M2H contain multiple changes from the
wild-type sequence at both the nucleotide and amino acid level. These
changes are found in both the 5′ untranslated region (UTR) and the
open reading frame (ORF) encoding the viral polyprotein (Fig. 3). The
changes within the coding region are located in the P1 structural and
P3 non-structural regions of the genome, speciﬁcally in VP1, VP3, and
3A. Both RV1A/M2M and RV1A/M2H shared several common changes
but contain unique silent mutations, indicating that each virus was iso-
lated independently.
Several individual molecular clones of wild-type RV1A contained the
N85D change in VP1 observed in the RV1A/M2M and the H5Y change in
VP3 observed in both RV1A/M2M and RV1A/M2H. Because these amino
acids are also present in database sequences of RV1A (Palmenberg et al.,
2009), they may represent normal ﬂuctuations within the viral popula-
tion. To evaluate the effect that these amino acid changes have on the
mouse cell-adapted phenotype, they were introduced into wild type
HRV1a. No differences were observed between viruses containing VP1
N85D/VP3 H5Y and wild-type virus in LA4 cells (Fig. 4), indicating that
changes in the structural proteins have no effect on RV1A adaptation
to efﬁcient growth in mouse cells.
Enhancement of viral replication in trans
Analysis of previously selected mouse cell-adapted RV2, RV16, and
RV39 indicates that the P2/P3 nonstructural proteins mediate changesd at different times post-infection by plaque assay. Graphs are labeled as follows: HeLa
quare), and RV1A/M2M or RV1A/M2H (inverted triangle). A. Replication of RV1A/M2M
lls. C. Replication of RV1A/M2M at MOI=0.1. D. Replication of RV1A/M2H at MOI=0.1.
Fig. 2. Cytopathic effect induced by infectionwithmouse-adaptedRV1A variants. At different times after infection, cell viabilitywasmeasuredby trypan blue exclusion. Graphs are labeled
as follows: HeLa cells (solid lines, solid symbols), LA4 cells (dashed lines, empty symbols), mock-infected cells (diamonds), wild-type RV1A (squares), RV1A/M2M (triangles), and
RV1A/M2H (inverted triangles). A. Cell viability in HeLa cells infected with RV1A. B. Cell viability in LA4 cells infected with RV1A.
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Yin and Lomax, 1983, 1986). Speciﬁcally, changes in protein 3A enhance
replication of RV39 in mouse ﬁbroblasts (Harris and Racaniello, 2005).
These changesmay promote interactionswith host proteins that are es-
sential for viral replication. If this hypothesis is correct, then it should be
possible to render mouse cells permissive for rhinovirus replication by
synthesis of P2/P3 proteins from picornaviruses that are competent
for growth inmouse cells. Mouse cells are permissive for the replication
of wild type poliovirus type 1/Mahoney (P1/M), indicating that the po-
liovirus P2/P3 proteins interact with the host machinery in a manner
that promotes viral replication. To determine whether poliovirus 2BC
or 3A proteins can enhance the growth of RV1A, stable LA4 cells were
produced by DNA-mediated transformation with plasmids encoding
the poliovirus proteins.We determined protein expression by immuno-
blotting (Fig. S1). RV1a replication was enhanced in cells that synthe-
size P1/M proteins 2BC and 3A, either individually or together (Fig. 5).
Viral replication in mice
RV1A/M2M was passaged seven times by intranasal inoculation in
BALB/c mice with intermittent ampliﬁcation in HeLa cells, producingFig. 3. Amino acid changes in RV1A/M2M and RV1A/M2H. Amino acid changes in RV1A/M2M
P1 (light gray), P2 (white), and P3 (dark gray) are identiﬁed by shading.virus RV1A/M2M7. When this virus was inoculated intranasally in
mice, virus titers in respiratory tissues declined 1000-fold within
24–48 h (data not shown). We considered that the respiratory mucosa
might act as a barrier to infection ofmicewith RV1A/M2M. In support of
this hypothesis, it has been shown that disruption of the intestinal mu-
cosal barrier is required to render poliovirus receptor transgenic mice
susceptible to poliovirus infection by oral inoculation (Kuss et al.,
2008). Hypochlorous acid and hydrogen peroxide have been shown to
increase respiratory permeability in a variety of rodent models in vivo
(Greiff et al., 1999; Guo et al., 1995, 1996). Therefore the effects of
these treatments on susceptibility of mice were determined. Mice
were instilled intranasallywith 30 μMhypochlorous acid or Ringer's so-
lution several hours prior to inoculation with RV1A/M2M7. Virus titers
in the respiratory tissues declined nearly 1000-fold with 24 h in mice
treated with Ringer's solution (Fig. 6). In contrast, virus titers declined
only slightly in respiratory tissues of mice treated with 30 μM hypo-
chlorous acid. These observations suggest that permeabilization of the
respiratory mucosa allows RV1A/M2M7 to penetrate to target cells
and replicate to levels sufﬁcient to maintain virus titer. Pre-treatment
of mice with 20 μmol hydrogen peroxide lead to a 100-fold drop in
virus titer 24 h following inoculation. Hydrogen peroxide might be less(top) and RV1A/M2H (bottom) are identiﬁed by arrows. Viral polyprotein precursors
Fig. 4. Effect of changes in RV1A capsid proteins on host range. At different times after
infection of LA4 or HeLa cells, viral yields were determined by plaque assay. RV1A
(square) was compared to RV1A-VP3/H5Y-VP1/N85D (triangle) in HeLa (solid line,
solid symbols) and LA4 cells (dashed line, empty symbols) at MOI=1.
Fig. 6. Effect of permeabilizing agents on RV1A/M2M replication in mice. BALB/cJ mice
(4–8 weeks old; n=3 per condition per time point) were intranasally instilled with
Ringer's solution (black bars), 30 μMhypochlorous acid (white bars), or 20 μmol hydrogen
peroxide and subsequently infectedwith 5×107 PFU RV1A/M2M. Viral titers in respirato-
ry organ homogenates were determined at 0 and 24 h post-infection by plaque assay.
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of the inoculum.
We determined the replication kinetics of RV1a in mice pre-treated
with hypochlorous acid. After intranasal inoculation with 8×106 PFU
of RV1A/M2M7, viral titers in the nose, trachea, and lungs were deter-
mined by plaque assay. Inmice infectedwithwild-type RV1A, viral titers
steadily decreased, andwere at the limit of detection of the plaque assay
after two days. In contrast, inmice infectedwith RV1A/M2M7, therewas
no decrease in virus titer by 24 h post-infection, and a ten-fold decreaseFig. 5. Growth of RV1A in LA4 cells producing 2BC and/or 3A from poliovirus type
1/Mahoney strain. Replication of wild-type RV1A was evaluated at MOI=1 in LA4
cells expressing empty pcDNA4-TO vector (squares), FLAG-P1/M 2BC (triangles),
FLAG-P1/M 3A (inverted triangles), or FLAG-P1/M 2BC and FLAG-P1/M 3A (dia-
monds). Viral titers were determined by plaque assay.48 h post-infection. These observations indicate that RV1A/M2M7 repli-
cates in themurine respiratory tract, while thewild-type RV1A does not.Discussion
The replication cycle of RVs is poorly understood on amolecular level,
in that speciﬁc host cell proteins required for permissive infection are
largely unknown. Most studies that focus on how picornavirus proteins
interact with the host cell to facilitate replication of viral RNA and pro-
duction of progeny virus have been carried out on poliovirus-infected
cells. As poliovirus is capable of robust replication in mouse cells, such
studies have not revealed species-speciﬁc host cell requirements for
viral growth.
Passage of RV1a in murine embryonic ﬁbroblasts yielded viruses
with amino acid changes in VP1, VP3, and 3A. Introduction of amino
acid changes into the capsid region of wild-type RV1A did not lead to
enhanced replication in mouse cells. It seems likely that the amino
acid change in 3A protein is responsible for the enhanced replication
of RV1a in mouse embryonic ﬁbroblasts. It is curious that 2BC protein
from P1/M alone was capable of enhancing wild-type RV1A replication
in mouse cells, despite the fact that changes in 2BC were not identiﬁed
in any of the mouse-adapted RV1A variants isolated in this study. This
observation suggests that multiple viral proteins are involved in the
function that is deﬁcient in mouse cells.
Previous studies have demonstrated that selection of RVs with im-
proved replication in mouse cells is accompanied by changes in the
viral 2BC and 3A proteins (Lomax and Yin, 1989; Yin and Lomax,
1983, 1986). The mechanism by which changes in these proteins en-
hance the permissivity of mouse cells is presently unknown. The results
of yeast two-hybrid studies have shown that the RV 3Aprotein interacts
with proteins involved in vesicular transport and lipid biosynthesis
(Harris and Racaniello, 2003, 2005). These ﬁndings are intriguing
given the essential role ofmembrane structures in picornavirus RNA rep-
lication (Quiner and Jackson, 2010). Furthermore, poliovirus has been
shown to subvert autophagic processes to generate double-membraned
vesicular structures needed for assembly of the viral replication complex,
with notable co-localization of poliovirus 3A and the autophagosomal
marker LC3 (Taylor and Kirkegaard, 2007, 2008). This observation is
also consistent with reports that GTPases regulating vesicular transport
and membrane lipid composition are required for assembly of special-
ized organelles supporting enterovirus replication (Belov et al., 2005,
2007b; Hsu et al., 2010; Lanke et al., 2009).
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associated membrane remodeling in rhinovirus-infected cells is unclear.
Although induction of autophagy does not enhance the growth of HRV2
and does not appear to be required for replication (Brabec-Zaruba et al.,
2007), the importance of 3A in membrane remodeling has been con-
served among many other members of genus Enterovirus. Furthermore,
amino acid changes in RV1A structural proteins have no effect on virus
replication, suggesting that mouse adaptation is mediated post-entry.
When synthesized alone, poliovirus 3A causes substantial swelling of
the ER membranes, but does not induce formation of membranous repli-
cation structures (Doedens and Kirkegaard, 1995). During infection, 3A
directly binds guaninenucleotide exchange factors (GEFs)mediating ac-
tivation and recruitment of ADP-ribosylation factor (Arf) family GTPases
that regulate anterograde ER-to-Golgi secretory trafﬁcking pathways
into the membranes associated with RNA replication complexes
(Belov et al., 2005, 2007a, 2008; Belov and Ehrenfeld, 2007; Doedens
and Kirkegaard, 1995). Amino acid changes in RV1A/M2M 3A may
enhance the ability of RV1A to interact with murine host proteins
required for these processes in the course of the viral life cycle.
It is likely that additional passaging of RV1A/M2M in vivo will select
for variants capable of more robust growth in the mouse respiratory
tract. However, development of more virulent mouse-adapted RV1A
variants may not eliminate the requirement for permeabilization of
the respiratory tract prior to experimental infection in this model. The
necessity for permeabilization may be a consequence of the remarkable
ability of the respiratory mucosa to prevent pathogens from accessing
the susceptible epithelial cells lining the airway. This requirement may
mimic the normal physiological factors predisposing human patients
to RV infection. It is well-documented that patients who smoke or are
exposed to cigarette smoke (Gryczynska et al., 1999; Jedrychowski and
Flak, 1997), are afﬂicted with cystic ﬁbrosis or similar pre-existing con-
dition (McManus et al., 2008), orwho have suffered another type of pul-
monary injury aremore susceptible to upper respiratory tract infections.
This enhanced susceptibility may be due to either direct mechanical in-
jury creating entry routes for virus, or by increased mucosal permeabil-
ity and enhanced RV receptor expression induced by inﬂammatory
mediators up-regulated in response to pulmonary damage (Altman et
al., 1993; Bianco et al., 2000; Subauste and Proud, 2001; Whiteman et
al., 2003). Furthermore, infants whohave not developed a fully differen-
tiated respiratory mucosa are also prone to contracting upper respirato-
ry infections. These data suggest that a loss of host mucosal barrier
integrity is a critical early step in RV pathogenesis, and may determine
host susceptibility. The fact that basal cells, located deeperwithin the re-
spiratory epithelium are more susceptible to rhinovirus infection
(Jakiela et al., 2008) is consistent with these observations.
Further studies should be conducted to characterize and improve
thismousemodel. Studies assessing cellular responses and cytokine ex-
pression to determine the breadth of the murine immune response are
underway, as are histopathology studies to determine the level of injury
and inﬂammation present in the mouse respiratory tract. This model
represents an advance in the ability to study both the pathogenesis of
RV infection and the development and pathogenesis of allergic sensiti-
zation and asthma in vivo.
Materials and methods
Cell lines and culture media
All cells were propagated in cell culture medium and supplements
from Invitrogen (Carlsbad, CA) unless otherwise speciﬁed. HeLa S3
cells were propagated in Dulbecco's Modiﬁed Eagle Medium (DMEM)
supplemented with 10% bovine calf serum (Hyclone, Logan, UT),
40 mM MgCl2, 20 mM HEPES buffer, and 1% penicillin/streptomycin.
LA4 mouse lung epithelial cells were propagated in F-12/Ham's Nutri-
ent Solution supplemented with 15% fetal bovine serum, 0.01% sodium
bicarbonate, 40 mM MgCl2, and 1% penicillin/streptomycin. MDA5−/−murine embryo ﬁbroblasts (MEFs) were generously provided by
Marco Colonna (Washington University, St. Louis, MO) and maintained
in DMEM supplemented with 10% fetal bovine serum, 1% nonessential
amino acids, and 1% penicillin/streptomycin.
LA4 cells stably expressing 2BC and/or 3A proteins from poliovirus
type 1/Mahoney strain were generated by introducing plasmid DNA
encoding the viral protein (pcDNA4-TO/FLAG-2BC and/or pcDNA4-TO/
FLAG-3A, kindly provided by Juliet Morrison) or with empty pcDNA4-
TO vector using Lipofectamine 2000 (Invitrogen). Prior to DNA-
mediated transformation, LA4 cells were cultured with varying concen-
trations of zeocin (Invitrogen) ranging from 100 μg/mL to 1 mg/mL for
10 days to determine the optimal concentration for selection. Fresh
LA4medium containing zeocin was added every 48 h. The optimal con-
centration was deﬁned as the lowest concentration needed to kill 100%
of the cells in the shortest amount of time. Ultimately, 1 mg/mL zeocin
was capable of killing over 90% of the cells in 8 days, with total cell
death occurring at this concentration at 9 or 10 days following applica-
tion of zeocin. LA4 medium containing 1 mg/mL zeocin was applied to
cells 24 h post-DNA transformation and maintained for 14–17 days
until colonies of thriving cells were observed. Production of FLAG-2BC
and/or FLAG-3A by these cell lines was determined by SDS-PAGE and
subsequent immunoblotting with M2 anti-FLAG antibody (Sigma-Al-
drich, St. Louis, MO).
Virus stocks
Human rhinovirus 1A (RV1A) was obtained from the American Type
Culture collection and stocks were prepared in HeLa S3 cells. Brieﬂy,
virus diluted in PBS containing 0.5% bovine serum albumin (VBS) was
adsorbed to conﬂuent HeLa cell monolayers for 1 h at 33 °C. HeLa cell
culture medium was added and cells were cultured for 24–72 h or
until 90% cytopathic effect was observed by light microscopy. Virus
titerwas determined on conﬂuent HeLa cellmonolayers by standard pla-
que assay in RV1A plaquingmedium composed of DMEM supplemented
with 2% bovine calf serum, 40 mMMgCl2, 0.01% sodium bicarbonate, 1%
penicillin/streptomycin, and 1% low-gelling type VII agarose (Sigma).
Cloning and sequencing of RV1A
Virus stocks of RV1A were centrifuged in a SW41 rotor (Beckman)
for 2 h at 35,000 rpm with a 2 mL cushion of 25% sucrose in PBS. The
pellet was resuspended directly in 1 mL TRIzol reagent (Invitrogen),
and RNA was prepared using the manufacturer's protocol. The RNA
pellet was brieﬂy air-dried and resuspended in 50 μL DEPC-treated
dH2O. First-strand cDNA was produced from viral RNA by reverse
transcription with Superscript III (Invitrogen) at 55 °C for 1 h using
oligo dT (Fermentas, Glen Burnie, MD), followed by a 30 min incuba-
tion with RNase H (Invitrogen).
Two ampliﬁed products were produced by PCR using Herculase II fu-
sion polymerase (Stratagene), encompassing the entire genomeof RV1A.
The ﬁrst PCR product comprising nucleotides 1-2655 was ampliﬁed
using the following primers designed to add a XmaI site to the 5′ termi-






The second PCR product comprising nucleotides 2632-7100 was
ampliﬁed using the following primers designed to add a ClaI site to
the 5′ terminus and a XhoI site to the 3′ terminus:
Forward (RV1A-ClaIfwd):
5′-GCGATCGATGGAAAATCACACTACAGGAAATGG-3′.
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5′-CGCCCTCGAGGTTTTTTTTTTTTTTTTATAGAATTAAAGAATCATTCAT-
TC-3′.
Each full-length PCR product was cleaved with XmaI and ClaI or ClaI
and XhoI and cloned into pACYC177 between the XmaI and ClaI sites
(pACYC177-5′RV1A) and the ClaI and XhoI sites (pACYC177-3′RV1A),
respectively. Both subclones were cleaved with XmaI and SacI, and the
2500 bp fragment from pACYC177-5′RV1A and the 7000 bp fragment
from pACYC177-3′RV1Awere gel puriﬁed using the QIAGEN Gel Puriﬁ-
cation Kit (QIAGEN) per manufacturer's instructions. The 7000 bp frag-
ment from pACYC177-3′RV1A was treated for 1 h with Antarctic
phosphatase (New England Biolabs, Ipswich, MA) at 37 °C.
Both fragments were ligated using T4 DNA ligase and propagated in
XL-10 Gold Ultracompetent E. coli (Stratagene/Agilent, Santa Clara, CA).
The complete nucleotide sequence was determined by sequencing
using primers designed to fully sequence both strands of infectious
clones and PCR products. The nucleotide sequences were aligned by
Geneious (Auckland, NZ) sequence analysis software, and a consensus
was determined and used as the reference for wild-type RV1A.Animals
Four-to-eight week old BALB/cJ mice (Jackson Laboratories) were
bred and maintained in a barrier facility according to institutional
animal care protocols. Mice were housed in microisolator cages and
fed sterilized food and water ad libitum. Infection experiments were
independently performed at least 3 times with 3–5 mice/condition/
timepoint/experiment. Mice were anesthetized with isoﬂurane gas
and intranasally instilled with 50 μL 30 mM hypochlorous acid to per-
meabilize the respiratory tract. Mice were allowed to recover 6–18 h
prior to isoﬂuorane anesthesia and intranasal instillation of 8×106 pla-
que forming units of either RV1A or RV1A/M2M in a 0.1 mL inoculum.
At 0 and 24 (Fig. 6), or 0, 24, and 48 h post-infection (Fig. 7), mice
were humanely sacriﬁced via asphyxiation with carbon dioxide gas.
Nose, trachea, and lungs were removed on ice, weighed, homogenized
in 1 mL phosphate-buffered saline using a Brinkmann tissue homoge-
nizer, and subjected to 3 freeze/thaw cycles. Homogenates were centri-
fuged to pellet solid tissue debris, and supernatants were ﬁltered
through 0.2 μm syringe ﬁlters (Nalgene). Virus titers from clariﬁed
organ homogenates were determined by plaque assay as described
above.
Supplementary materials related to this article can be found
doi:10.1016/j.virol.2011.08.021.Fig. 7. Replication of RV1A/M2M-7 in HOCl-treated BALB/cJ mice. Mice (4–8 week old,
3–5 mice per time point per condition) were infected intranasally with wild-type RV1A
(squares) or RV1A/M2M-7 (triangles). Organs were harvested and homogenized at dif-
ferent times after infection and viral titers were determined by plaque assay.Acknowledgments
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